This section of the website is only for UK patients that have been prescribed KEYTRUDA® (pembrolizumab).

 
HomeYour treatment
 

You are about to exit this MSD website.

MSD makes no warranties or representations of any kind as to the accuracy, completeness, reliability or usefulness of any information contained in third party sites and shall have no liability for any loss or damage of any kind that may arise from your use of such content or information.

Inclusion of any third party link does not imply an endorsement or recommendation by MSD.

CLOSE
CONTINUE TO EXTERNAL SITE

GB-PDO-01312 | Date of Preparation: November 2020


This page is currently being built

In the meantime please refer to the KEYTRUDA® (pembrolizumab) head and neck squamous cell carcinoma treatment diaries available for download below

PDF 5 MB

KEYTRUDA® (pembrolizumab) monotherapy patient diary for HNSCC patients

This diary has been designed for patients receiving KEYTRUDA monotherapy for the treatment of head and neck squamous cell carcinoma.

This diary contains information about KEYTRUDA monotherapy, including how it is given, how it works, possible side-effects and what you should do if you notice any signs or symptoms.

It is also designed to support your treatment journey by providing space to:

  • Record any questions you might have
  • Note down future appointment dates
  • Write notes for you from your healthcare profession
Download

PDF 5 MB

KEYTRUDA® (pembrolizumab) in combination with chemotherapy patient diary for HNSCC patients

This diary has been designed for patients receiving KEYTRUDA in combination with chemotherapy for the treatment of head and neck squamous cell carcinoma.

This diary contains information about KEYTRUDA in combination with chemotherapy, including how it is given, how it works, possible side-effects and what you should do if you notice any signs or symptoms.

It is also designed to support your treatment journey by providing space to:

  • Record any questions you might have
  • Note down future appointment dates
  • Write notes for you from your healthcare profession
Download

Supporting documentation

KEYTRUDA® (pembrolizumab)

Summary of Product Characteristics | Patient Information Leaflet

GB-OHN-00248 | Date of Preparation: December 2020


GB-PDO-01246 | Date of Preparation: November 2020

Privacy Policy | Terms of Use | Contact Us

Reporting side effects: if you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk.

MSD

Merck Sharp & Dohme (UK) Limited Registered Office: 120 Moorgate, London, EC2M 6UR. A company registered in England and Wales. Company Registration Number: 233687. Merck Sharp & Dohme (UK) Limited, © 2020. All rights reserved.